Table 1.

Recommended therapy management after index event

	Study population n = 72
Therapy recommendation
ASA	59 (81.9%)
Clopidogrel	28 (38.8%)
Prasugrel	2 (2.8%)
Ticagrelor	4 (5.6%)
OAC	12 (16.6%)
LWMH once per day	1 (1.4%)
Statin	47 (65.3%)
Beta-blocker	63 (87.5%)
ACE inhibitor/AT inhibitor	63 (87.5%)
Mineralocorticoid receptor antagonist	31 (43.1%)
Duration of antithrombotic therapy
No recommendation	41 (56.9%)
With recommendation:	29 (40.3%)
1 month	4 (5.6%)
3 months	8 (11.1%)
6 months	6 (8.3%)
12 months	11 (15.3%)
Reason for OAC
Atrial fibrillation	10 (13.8%)
Heart failure	1 (1.4%)
Deep vein thrombosis	1 (1.4%)

Data is presented as number of patients and percentage

LWMH low weight molecular heparin, OAC oral anticoagulation

Antithrombotic therapy includes antiplatelet mono- or dual therapy or oral anticoagulation